Adults 18 to 100, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Activity Tracker Utilization- Total Days of UsePrimary· 3 months
Descriptive statistics, such as mean for the number of days of use over the three month period
Group
Value
95% CI
CF Patients Using Fitbit for 3 Months
85.380
27 – 93
Activity Tracker Utilization - Minutes of Sleep Per NightPrimary· 3 months
Descriptive statistics, such as mean for the number of minutes per sleep per night
Group
Value
95% CI
CF Patients Using Fitbit for 3 Months
381.28
0 – 983
Activity Tracker Utilization - Steps Per DayPrimary· 3 months
Descriptive statistics, such as mean, for the number of steps per day
Group
Value
95% CI
CF Patients Using Fitbit for 3 Months
7262.49
0 – 30010
Integration of Cystic Fibrosis Registry Lung Function Data - Average GLI FEV1 From First to Last Day of Fitbit WearSecondary· 3 months
Analyze the data trends. Forced Expiratory Volume (FEV1) reported will be used for small group analysis to compare trends with lung function mean from first to last day of wear.
Group
Value
95% CI
CF Patients Using Fitbit for 3 Months
66.535
30.42 – 117.69
Sponsor's own description
STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis Using Integration Of Fitness Technology and Port CF. A pilot in integration of wearable fitness tracker data with existing health data provided by CF foundation Patient Registry (Port CF)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
· Phase 1
· recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
· Phase 1
· recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
· recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation.
· Phase 3
· recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI
· Phase 1, PHASE2
· active not recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease
· not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics
· NA
· not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes
· NA
· not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM
· Phase 1, PHASE2
· not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04018495.